Comparison of antibody responses to human papillomavirus vaccination as measured by three assays

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  Robbins, Hilary A ^a   Kemp, Troy J ^b   Porras, Carolina ^c   Rodriguez, Ana Cecilia ^c   Schiffman, Mark ^a   Wacholder, Sholom ^a   Gonzalez, Paula ^c,d   Schiller, John ^a   Lowy, Douglas ^a   Poncelet, Sylviane ^e   Esser, Mark ^f   Matys, Katie ^g   Hildesheim, Allan ^a   Pinto, Ligia A ^b   Herrero, Rolando ^c,d   Safaeian, Mahboobeh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f MEDIMMUNE   (United States)

^g PPD Vaccines and Biologics Center of Excellence   (United States)

Author keywords

Clia; Elisa; HPV serology; HPV vaccines; Human papillomavirus; Seap na

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL (TOPIC); COMPETITIVE LUMINEX IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOASSAY; IMMUNOGENICITY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PAPILLOMAVIRUS VACCINATION; SECRETED ALKALINE PHOSPHATASE NEUTRALIZATION ASSAY; SEROCONVERSION; SEROPREVALENCE; VACCINATION;

EID: 84893669936     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00328     Document Type: Article

References (18)

1. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 30(Suppl 5):F123-38. doi:10.1016/j.vaccine.2012.04.108
2. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 102:325-39. doi:10.1093/jnci/djp534
3. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2012) 13:89-99. doi:10.1016/S1470-2045(11)70286-8
4. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) (2012) 5:18-23. doi:10.1158/1940-6207.CAPR-11-0542
5. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 10:681-92. doi:10.1038/nrmicro2872
6. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 321:205-16. doi:10.1016/j.virol.2003.12.027
7. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 10:108-15. doi:10.1128/CDLI.10.1.108-115.2003
8. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis (2009) 200:166-71. doi:10.1086/599988
9. Safaeian M, Ghosh A, Porras C, Lin SW, Rodriguez AC, Schiffman M, et al. Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev (2012) 21:1547-54. doi:10.1158/1055-9965.EPI-12-0558
10. Kemp TJ, Garcia-Pineres A, Falk RT, Poncelet S, Dessy F, Giannini SL, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 26:3608-16. doi:10.1016/j.vaccine.2008.04.074
11. Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One (2013) 8:e53067. doi:10.1371/journal.pone.0053067
12. Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol (2011) 18:418-23. doi:10.1128/CVI.00489-10
13. Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C, Solomon D, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 26:4795-808. doi:10.1016/j.vaccine.2008.07.002
14. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 29:2011-4. doi:10.1016/j.vaccine.2011.01.001
15. Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix((R)). Vaccine (2012) 31:165-70. doi:10.1016/j.vaccine.2012.10.067
16. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin (2008) 4:425-34. doi:10.4161/hv.4.6.6912
17. Dias D, Van DJ, Schlottmann S, Kelly S, Puchalski D, Ruiz W, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 12:959-69. doi:10.1128/CDLI.12.8.959-969.2005
18. Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin (2011) 7:230-8. doi:10.4161/hv.7.2.13948xs